New antibody drug targets deadly heart shock in early trial

NCT ID NCT06832722

Recruiting now Disease control Sponsor: 4TEEN4 Pharmaceuticals GmbH Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This early-stage trial tests a new antibody drug called procizumab in 130 people with cardiogenic shock, a life-threatening condition where the heart cannot pump enough blood. The drug blocks a protein called DPP3, which is linked to worse outcomes. The main goal is to check safety and find the right dose, not yet to prove it works.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

procizumab (also called invobenitug or AK1967), a monoclonal antibody

What this could lead to

If it works, this could point toward a new treatment for cardiogenic shock, a life-threatening condition with few options.

What could go wrong

This is an early phase 1b/2a trial with only 130 participants, so it is primarily testing safety and dosing. The drug may not improve survival or heart function, and side effects are unknown.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cardiogenic shock Shock, Cardiogenic

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SHOCK, CARDIOGENIC

Contacts and locations

Show contact details

Study contacts

Contact
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Charles University Motol University Hospital
RECRUITING

Prague, Czechia

Contact
Clinical University Hospital Poznań
RECRUITING

Poznan, Poland

Contact Email: •••••@•••••
Département d'anesthésie-réanimation
NOT_YET_RECRUITING

Dijon, 21000, France

Contact
Erebouni Mwdical Center
NOT_YET_RECRUITING

Yerevan, 0087, Armenia

Contact
General University Hospital in Prague - FVN
RECRUITING

Prague, Czechia

Contact Phone: •••-•••-•••• Email: •••••@•••••
Górnośląskie Centrum Medyczne w Katowicach / Śląski Uniwersytet Medyczny w Katowicach
RECRUITING

Katowice, Poland

Contact
Heart Center Aalst, AZORG
RECRUITING

Aalst, Belgium

Contact
Hôpital Pitié Salpêtrière
NOT_YET_RECRUITING

Paris, 75651, France

Contact
Institute of Clinical and Experimental Medicine - IKEM
RECRUITING

Prague, Czechia

Contact Phone: •••-•••-•••• Email: •••••@•••••
J. Mikulicz Radecki Clinical University Hospital Wrocław
RECRUITING

Wroclaw, Poland

Contact Phone: •••-•••-•••• Email: •••••@•••••
Lariboisière Hospital AP-HP
RECRUITING

Paris, France

Contact Phone: •••-•••-•••• Email: •••••@•••••
Radboud University Medical Center
RECRUITING

Nijmegen, Netherlands

Contact Email: •••••@•••••
Regional University Hospital Nancy - Hopitaux de Brabois
RECRUITING

Nancy, France

Contact Phone: •••-•••-•••• Email: •••••@•••••
Uniersytecki Szpital Kliniczny w Białystoku
RECRUITING

Bialystok, Poland

Contact
University Hospital - Dupuytren Limoges
RECRUITING

Limoges, France

Contact Email: •••••@•••••
University Hospital Avicenne AP-HP
RECRUITING

Bobigny, France

Contact Email: •••••@•••••
University Hospital Lille - Institut Cœur Poumon
RECRUITING

Lille, France

Contact Phone: •••-•••-•••• Email: •••••@•••••
University Hospital Saint Pierre
RECRUITING

Brussels, Belgium

Contact Phone: •••-•••-•••• Email: •••••@•••••
University Hospital and Medical Faculty of Pilsen
RECRUITING

Pilsen, Czechia

Contact
Yerevan medical scientific center
NOT_YET_RECRUITING

Yerevan, 0014, Armenia

Contact